AC IMMUNE WKN: A2AR5F ISIN: CH0329023102 Kürzel: IMR Forum: Aktien Thema: Hauptdiskussion

Meine Meinung schon krass wie beide Aktien dieses Jahr gelaufen sind unaufhaltsam Richtung Süden

Game Over genauso ein dreck wie curevac und findet ihr da die Verbindung ???

Aktie Tot ‼️‼️‼️‼️

Was ist denn jetzt @andi28xx ? Am Mittwoch noch geschrieben, ob es under ernst sei 😂. Die 0‘…€ werden kommen ❗️ Werden wir alle noch sehen, sehr sehr bald‼️

Der größte Schrott

Oh man euer Ernst jetzt ???

@lockstoff Die 0,..€ werden noch kommen

immune hat und auch noch ein frühes weihnachtsgeschenk vorbei gebracht, endlich mal die 1,x vorne gesehen, ob es noch weitere geschenke gibt??? hmm bin js von 0,xx ausgegangen

2€ 👏🏻👏🏻👏🏻👏🏻👍👍 besser so @Caspar Weiter so Ac immune. Deine pipeline ist stark 🦾

Gibts was neues ausser dass die Aktie mal wieder Rot ist???

Ich gehe mit denen, den Bach unter. !

Ist doch vollkommen ok deine Meinung. Verkauf und investiere in was anderes. Es ist aber albern in meinen Augen hier ständig deine negative, subjektive Meinung zu posten.

Ich lasse mich eines besseren belehren, jedoch bin ich mir sicher, dass die nichts können

Das ist nur 1 Produkt von der Pipeline

AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidate Based on this new clinical data, ACI-35.030 has been selected for further development representing significant progress for the anti-pTau vaccine candidate AC Immune vaccine portfolio targeting three hallmark proteins of neurodegenerative diseases now progressing through advanced clinical development Lausanne, Switzerland, November 30, 2022 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development. The ACI-35.030 anti-pTau vaccine candidate is being developed in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer's disease (AD). The excellent performance of ACI-35.030 in the trial participants (average age approximately 65 years) potentially opens promising avenues for AD treatment and prevention, which could offer an important societal impact. We thank the team at Janssen for their contributions of valuable knowledge, expertise, and resources to support this collaboration." The selection of ACI-35.030 is supported by new clinical data from the Phase 1b/2a trial presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2022. The results show that ACI-35.030 treatment rapidly leads to the strong and durable induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, ePHF. The ACI-35.030-induced antibody response was sustained and could be periodically boosted over a period of 72 weeks. The vaccine candidate was generally well tolerated. The decision to select ACI-35.030 follows the comparison, presented at CTAD, demonstrating its strengths relative to a protein conjugate vaccine, JACI-35.054, an alternative anti-pTau vaccine also being evaluated in parallel in the Phase 1b/2 trial. Dr. Andrea Pfeifer, CEO of AC Immune SA, added: "Looking forward into 2023 AC Immune will have three vaccine candidates in Phase 2 development, highlighting the Company's position as a leader in active vaccination for neurodegenerative diseases. Importantly, our vaccine programs are complemented by additional therapeutic and diagnostic candidates driving our precision medicine approach in neurodegenerative diseases. Some programs have already generated significant revenues from collaborations with companies such as Janssen, Eli Lilly, Genentech (Roche), and Life Molecular Imaging. Collectively, these programs form the most comprehensive pipeline in neurodegenerative disease, with clinical candidates targeting Tau, Abeta, and alpha-synuclein. We look forward to advancing these programs towards additional value creating milestones as our pipeline matures and grows."